AZD8931
Phase 2Small molecule
AstraZenecaAZD8931 is one of 27 small molecule programs targeting Breast Cancer. It is currently in Phase 2.
1
Indications
11
Total Trials
1
Active Trials
26
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Lexiscan
AstellasPreclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
AZD8931
AstraZenecaPhase 2
Vfend
PPrism Pharmaceuticals
Preclinical
Ablavar
LLantheus Medical Imaging
Preclinical
Naltrexone/bupropion
Novo NordiskPreclinical
Tc99m Sestamibi
MM.D. Anderson Cancer Center
Preclinical
Sertraline ODT
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Liposomal Irinotecan and Apatinib
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Preclinical
Ibrance
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Breast Cancer3 trials
Gastric Cancer1 trial
4 more indications
Absorption1 trial
Paclitaxel1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AZD8931. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company